Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

NCT02428855 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02428855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02428855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2015
Completion date
February 28, 2018
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma